spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  recombinant human hyaluronidase 

 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jun 2024
Halozyme Announces Roche's OCREVUS(R) SC with ENHANZE(R) Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jun 2021
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE(R) drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 19 Jul 2019
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX(R) Utilizing ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery Regulatory
 HSMN NewsFeed - 22 May 2019
Halozyme Announces argenx Has Selected Second Target Under ENHANZE(R) Technology Collaboration And License Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 4 Feb 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 17 Sep 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 21 Dec 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 May 2014
Baxter Provides U.S. Regulatory Update on HyQvia, Its Investigational Subcutaneous Treatment for Primary Immunodeficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Feb 2011
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera(R) (rituximab)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Oct 2009
Baxter Announces the Commercial Launch of HYLENEX at ACEP for Use in Pediatric Rehydration
Biopharmaceuticals
 HSMN NewsFeed - 15 Jul 2009
Baxter and Halozyme Announce Completion of Patient Enrollment in Phase III Pivotal Trial of GAMMAGARD LIQUID with rHuPH20 Enzyme
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2009
Data Presented at AAAAI Reinforce Baxter's Commitment to Making GAMMAGARD LIQUID Therapy More Convenient
Biopharmaceuticals
 HSMN NewsFeed - 23 Sep 2008
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2008
Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
Biopharmaceuticals
 HSMN NewsFeed - 10 Sep 2007
Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 14 Feb 2007
Halozyme Therapeutics and Baxter Present Promising Results for the Use of HYLENEX From the Infuse-Morphine Study
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2007
Halozyme and Baxter Expand Global HYLENEX Collaboration
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2006
Halozyme and Roche Enter Agreement for the Application of Enhanze, A Novel Technology to Improve Drug Delivery
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 8 Nov 2006
Halozyme Therapeutics Names William Fallon Vice President, Manufacturing & Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2006
Halozyme and Baxter Announce Availability of Hylenex for Subcutaneous Delivery of Medications and Fluids
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
Halozyme Therapeutics Announces FDA 510(k) Clearance for MediCult's SynVitro Cumulase Product
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 9

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 9 additional stories matching:
recombinant human hyaluronidase
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.